The estimated Net Worth of Lilly & Co Eli is at least $90 millió dollars as of 8 December 2020. Lilly Eli owns over 300,000 units of Sigilon Therapeutics stock worth over $61,667,634 and over the last 14 years Lilly sold SGTX stock worth over $28,309,003.
Lilly has made over 17 trades of the Sigilon Therapeutics stock since 2011, according to the Form 4 filled with the SEC. Most recently Lilly bought 300,000 units of SGTX stock worth $5,400,000 on 8 December 2020.
The largest trade Lilly's ever made was selling 700,000 units of Sigilon Therapeutics stock on 6 November 2018 worth over $9,800,000. On average, Lilly trades about 99,870 units every 165 days since 2010. As of 8 December 2020 Lilly still owns at least 2,744,443 units of Sigilon Therapeutics stock.
You can see the complete history of Lilly Eli stock trades at the bottom of the page.
Lilly's mailing address filed with the SEC is Eli Lilly and Company Corporate Center, Indianapolis, Marion County, Indiana, United States.
Over the last 4 years, insiders at Sigilon Therapeutics have traded over $2,000,000 worth of Sigilon Therapeutics stock and bought 2,018,493 units worth $31,039,916 . The most active insiders traders include Lilly & Co Eli, Lilly & Co Shenandoah Acqui... és John Cox. On average, Sigilon Therapeutics executives and independent directors trade stock every 139 days with the average trade being worth of $7,174,671. The most recent stock trade was executed by Lilly & Co Shenandoah Acqui... on 11 August 2023, trading 1,718,493 units of SGTX stock currently worth $25,639,916.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sigilon Therapeutics executives and other stock owners filed with the SEC include: